Live Tumor Board! Experts Navigate the Impact of Neutropenia Across Tumor Types

Target Audience
This educational activity is directed toward medical oncologists, hematologists, fellows, surgical oncologists, and radiation oncologists interested in treatment of patients with cancer. Nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of cancer may also participate.

Activity Overview
This online, on-demand virtual symposium brings together renowned international experts from several fields of cancer care clinical research to discuss the challenges associated with management of neutropenia. In this educational program, didactic and case presentations will investigate the use of prophylactic growth factors (granulocyte colony-stimulating factors; G-CSF) and biosimilars in patients receiving induction chemotherapy regimens that convey high risk for developing febrile neutropenia. Expert analyses will include a look at both the benefits and limitations associated with approved strategies. This activity will also include a comprehensive discussion of recent data from clinical trials of emerging agents in this space that aim to address unmet needs in cancer patients, including common quality of life issues, such as bone pain, that can arise from G-CSF regimens.

This educational activity is an archive of the live virtual webcast held on June 7, 2021.

Learning Objectives
Upon successful completion of this activity, you should be better prepared to:

Evaluate patient-, disease-, and treatment-specific characteristics used to stratify risk level for neutropenia and febrile neutropenia development during cancer treatment
Discuss the impact of CIN and unmet clinical needs in the management of neutropenia and role of emerging therapies to improve quality of life across tumor settings
Assess the efficacy and safety profiles of emerging therapeutics evaluated for the management of neutropenia across tumor types
Apply evidence from landmark trials to develop proactive management plans for real-world case scenarios in the treatment of neutropenia